Last reviewed · How we verify
NCT04926116
A Study of AK3280 in Chinese Healthy Volunteers
Phase 1 trial testing AK3280 in Healthy in 24 participants. Completed in 28 September 2021.
28 September 2021
Quick facts
| Lead sponsor | Shanghai Ark Biopharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 9 June 2021 |
| Primary completion | 28 September 2021 |
| Estimated completion | 28 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- AK3280
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Shanghai Ark Biopharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a randomized, double-blind, placebo-controlled, single-center, phase I study to evaluate the safety, tolerability, and pharmacokinetics of AK3280 in healthy Chinese subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04926116
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AK3280
Trials testing the same drug.
- NCT03990688 — A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects · Phase 1 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Shanghai Ark Biopharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06591845 — Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects · Phase 1 · not yet recruiting
- NCT06942299 — A Study of AK0529 in Adults Patients Hospitalized With RSV Infection · Phase 2 · completed
- NCT04788017 — A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects · Phase 1 · completed
- NCT04231968 — A Study of AK0529 in Chinese Infants Hospitalized With RSV · Phase 3 · completed
- NCT03990688 — A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04926116 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Ark Biopharmaceutical Co., Ltd.
- Last refreshed: 7 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04926116.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing